MTST (MetaStat) YoY EBITDA Growth: -212.32% (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MetaStat YoY EBITDA Growth?

MetaStat MTST YoY EBITDA Growth is -212.32% as of Feb. 2018.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MetaStat's YoY EBITDA Growth for the quarter that ended in Feb. 2018 was -212.32%.

MetaStat's EBITDA per Share for the three months ended in Feb. 2018 was $-0.16.

MetaStat YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MetaStat's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat YoY EBITDA Growth Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -104.77 -19.02 46.84 74.26 8.82

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.71 90.25 36.15 42.43 -212.32

MetaStat YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MetaStat's YoY EBITDA Growth for the fiscal year that ended in Feb. 2018 is calculated as:

YoY EBITDA Growth (A: Feb. 2018 )
=(EBITDA per Share (A: Feb. 2018 )-EBITDA per Share (A: Feb. 2017 ))/ | EBITDA per Share (A: Feb. 2017 ) |
=(-0.548--0.601)/ | -0.601 |
=8.82 %

MetaStat's YoY EBITDA Growth for the quarter that ended in Feb. 2018 is calculated as:

YoY EBITDA Growth (Q: Feb. 2018 )
=(EBITDA per Share (Q: Feb. 2018 )-EBITDA per Share (Q: Feb. 2017 )) / | EBITDA per Share (Q: Feb. 2017 )) |
=(-0.155-0.138)/ | 0.138 |
=-212.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -212.32% mean?
MetaStat (MTST) has a YoY EBITDA Growth of -212.32% as of Feb. 2018. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MetaStat and its competitors.
Is MetaStat's YoY EBITDA Growth too high?
MetaStat's current YoY EBITDA Growth is -212.32%.
How does MetaStat's YoY EBITDA Growth compare to OBMP and NSPX?
MetaStat's YoY EBITDA Growth of -212.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MetaStat and its competitors. MetaStat's current YoY EBITDA Growth is -212.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current YoY EBITDA Growth of -212.32%. The current YoY EBITDA Growth is -212.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MetaStat (MTST), the current YoY EBITDA Growth is -212.32% as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.